Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.…
Why Did Omeros (OMER) Stock Move Today?
Omeros (NASDAQ: OMER) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 175 employees.
The shares were at 13.21 USD on 20 November 2026, up 100.8% over 52 weeks. Its 52-week range is 6.240 USD to 21.24 USD: the price is 37.8% below the high and 111.7% above the low.
At a market capitalisation of 983.66M USD, it trades at 15.9 times trailing earnings and 12.0 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a discount of 52% for OMER.
Omeros reports return on equity of 2.8% and an operating margin of -56.4%.
Its debt exceeds its cash by 98.55M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 2 analysts cover the stock, with an average rating of Buy; their mean price target of 27.50 USD is 108.2% above the current price. The next earnings report is expected on 31 March 2027.